respiratori
syncyti
viru
rsv
lead
caus
pediatr
viral
respiratori
tract
infect
neither
vaccin
effect
antivir
therapi
avail
prevent
treat
rsv
infect
palivizumab
human
monoclon
antibodi
product
approv
prevent
seriou
rsv
infect
high
cost
prohibit
lowincom
countri
aim
identifi
effect
safe
afford
antivir
agent
preexposur
prophylaxi
prep
rsv
infect
children
high
risk
found
maleic
anhydrid
ml
modifi
human
serum
albumin
hsa
design
mlhsa
exhibit
potent
antivir
activ
rsv
percentag
modifi
lysin
argini
mlare
correl
antirsv
activ
mlhsa
inhibit
rsv
entri
replic
interact
viral
g
protein
block
rsv
attach
target
cell
mlha
neither
bound
virus
f
protein
inhibit
f
proteinmedi
membran
fusion
intranas
administr
mlhsa
rsv
infect
result
signific
decreas
viral
titer
lung
mice
mlhsa
show
promis
develop
effect
safe
afford
easytous
intranas
regimen
preexposur
prophylaxi
rsv
infect
children
high
risk
lowand
highincom
countri
human
respiratori
syncyti
viru
rsv
member
paramyxovirida
famili
negativesens
rna
virus
lead
caus
virusinduc
sever
lower
respiratori
tract
diseas
infant
children
well
morbid
mortal
elderli
peopl
immunocompromis
adult
estim
million
case
acut
lower
respiratori
infect
alri
caus
rsv
infect
children
younger
year
occur
infect
children
die
alri
unit
state
hospit
million
children
year
age
requir
medic
attent
year
rsv
infect
virtual
everi
child
infect
rsv
given
age
neither
vaccin
effect
antivir
therapi
current
avail
prevent
treat
rsv
infect
palivizumab
trade
name
synagi
human
murin
monoclon
antibodi
mab
specif
rsv
f
glycoprotein
neutral
fusion
inhibitori
activ
rsv
approv
us
food
drug
administr
fda
passiv
immunoprophylaxi
use
among
infant
high
risk
includ
born
prematur
chronic
lung
diseas
congenit
heart
diseas
howev
high
cost
per
vial
palivizumab
june
prevent
use
lowincom
countri
mab
maintain
transport
low
temperatur
furthermor
palivizumab
must
prescrib
pediatrician
physician
intramuscularli
inject
doctor
offic
hospit
clinic
make
use
inconveni
ideal
prophylact
rsv
drug
effect
safe
afford
easi
use
infant
elderli
therefor
aim
identifi
antivir
agent
expect
effect
safe
palivizumab
afford
easier
use
preexposur
prophylaxi
prep
rsv
infect
among
infant
high
risk
previou
studi
demonstr
anhydridemodifi
protein
exhibit
potent
antivir
activ
human
immunodefici
viru
herp
simplex
viru
hsv
human
papillomaviru
hpv
found
anhydridemodifi
protein
particularli
anhydrid
hp
maleic
anhydrid
ml
modifi
bovin
albumin
bsa
human
serum
albumin
hsa
exhibit
potent
inhibitori
activ
rsv
select
mlmodifi
hsa
mlhsa
studi
ml
much
cheaper
hp
hsa
much
safer
bsa
human
use
mechan
studi
indic
mlhsa
inhibit
rsv
entri
replic
block
rsv
attach
target
cell
though
interact
viral
g
protein
intranas
administr
mlhsa
rsv
challeng
led
signific
decreas
viral
titer
lung
mice
suggest
mlhsa
may
use
prep
rsv
infect
children
high
risk
anhydrid
hp
maleic
anhydrid
ml
succin
anhydrid
su
human
serum
albumin
hsa
chicken
ovalbumin
ova
bovin
serum
albumin
bsa
purchas
sigma
st
loui
mo
usa
cell
count
bought
dojindo
molecular
technolog
inc
dojindo
japan
acid
tnb
purchas
sigma
purchas
fisher
scientif
co
valley
park
va
usa
purchas
sigma
antirsv
antibodi
leica
biosystem
leica
biosystem
newcastl
ltd
newcastl
upon
tyne
uk
rabbit
antimous
hrp
antibodi
purchas
dako
dako
glostrup
denmark
low
melt
point
agaros
bought
invitrogen
invitrogen
carlsbad
ca
usa
cell
vero
cell
obtain
american
type
cultur
collect
atcc
flpin
cell
obtain
invitrogen
maintain
eagl
minim
essenti
medium
dmem
gibcobrl
grand
island
ny
usa
supplement
fetal
bovin
serum
fb
gibco
mm
lglutamin
u
penicillin
ng
streptomycin
per
ml
rsv
long
strain
purchas
atcc
grown
cell
vector
purchas
invitrogen
vector
encod
f
protein
rsv
provid
dr
bin
wang
fudan
univers
viral
titer
determin
plaqu
assay
previous
describ
briefli
serial
dilut
rsv
long
strain
dmem
fb
use
infect
monolay
plate
cell
per
well
duplic
h
viru
attach
cell
inocula
remov
wash
phosphat
buffer
solut
pb
infect
cell
overlaid
fb
dmem
contain
low
melt
point
agaros
incub
five
day
later
plaqu
develop
cell
fix
paraformaldehyd
remov
agaros
viral
plaqu
visual
immunoperoxidas
stain
mous
antirsv
antibodi
primari
antibodi
pb
hrpconjug
rabbit
antimous
igg
secondari
antibodi
dilut
pb
hrp
color
develop
reagent
biorad
hercul
ca
usa
use
color
develop
plaqu
protein
modif
conduct
previous
describ
briefli
protein
dissolv
phosphat
final
concentr
mgml
subsequ
anhydrid
hp
maleic
anhydrid
ml
succin
anhydrid
su
ad
respect
five
aliquot
interv
ph
adjust
optim
condit
anhydrid
modif
hsa
modifi
mm
anhydrid
hp
ml
su
respect
mixtur
kept
anoth
h
room
temperatur
extens
dialyz
pb
protein
concentr
determin
pierc
bca
protein
assay
kit
thermo
rockford
il
usa
determin
lysin
residu
modifi
unmodifi
protein
tnb
assay
perform
previous
describ
briefli
ph
ad
modifi
unmodifi
protein
min
room
temperatur
tnb
pb
ad
mixtur
h
stop
solut
mm
ad
termin
reaction
absorb
nm
measur
micropl
reader
infinit
pro
tecan
research
triangl
park
nc
usa
assay
util
measur
percentag
arginin
residu
modif
perform
previous
describ
mm
ad
anhydridemodifi
unmodifi
protein
dissolv
sodium
phosphat
ph
kept
room
temperatur
dark
min
absorb
nm
measur
vitro
cytotox
anhydridemodifi
unmodifi
hsa
target
cell
use
measur
rsv
infect
vero
measur
kit
accord
manufactur
instruct
briefli
modifi
unmodifi
protein
grade
concentr
ad
equal
volum
cell
ml
well
plate
incub
day
solut
ad
h
incub
absorb
nm
determin
elisa
reader
infinit
pro
assay
cell
protect
describ
previous
use
assess
antivir
activ
anhydridemodifi
protein
brief
cell
seed
plate
cell
per
well
serial
dilut
protein
ad
plate
cell
infect
plaqueform
unit
pfu
rsv
long
strain
moi
cultur
five
day
cell
viabil
examin
kit
describ
investig
mechan
action
mlhsa
rsv
timeofaddit
temperatur
shift
assay
perform
previous
describ
monolay
cultur
cell
infect
pfu
moi
rsv
long
strain
absenc
presenc
mlhsa
final
concentr
nm
mlhsa
ad
plate
h
postinfect
h
postinfect
supernat
collect
inhibit
rsv
infect
determin
plaqu
assay
describ
temperatur
shift
assay
cell
plate
describ
expos
rsv
long
strain
presenc
variou
amount
mlhsa
heparin
rsv
attach
inhibitor
includ
control
h
incub
cell
wash
icecold
pb
twice
replac
fresh
medium
control
cell
presenc
mlhsa
heparin
wash
plate
move
incub
cultur
day
cytopath
effect
cpe
determin
kit
describ
previou
section
investig
whether
mlhsa
could
inhibit
rsv
f
proteinmedi
cellcel
fusion
syncytium
format
perform
cellcel
fusion
assay
base
fact
rsv
f
protein
express
cell
surfac
mediat
cell
fusion
neighbor
cell
construct
cell
express
f
protein
rsv
f
gene
rsv
fuse
gfp
cterminu
clone
vector
cotransfect
flpin
cell
ratio
h
transfect
cell
split
ad
zeocin
invitrogen
hydromycin
b
invitrogen
cell
per
well
seed
plate
incub
h
tetracyclin
dmso
ad
induc
f
protein
express
cell
mlhsa
nm
hsa
nm
nm
f
protein
inhibitor
ad
cell
cocultur
h
cellcel
fusion
syncytium
format
visual
microscopi
nikon
eclips
ts
nikon
tokyo
japan
determin
interact
mlhsa
rsv
g
protein
perform
elisa
assay
previous
describ
briefli
rsv
g
protein
extracellular
domain
provid
dr
b
wang
fudan
univers
coat
plate
incub
overnight
plate
block
gelatin
pb
h
follow
incub
hsa
mlhsa
serial
dilut
pb
min
antihsa
antibodi
abcam
hong
kong
ad
incub
h
horseradish
peroxidas
hrp
conjug
goat
antihuman
igg
antibodi
dako
glostrup
denmark
dilut
ad
incub
h
plate
wash
step
tween
pb
plate
develop
use
tmb
peroxidas
substrat
sigma
absorb
nm
measur
use
elisa
reader
infinit
pro
interact
mlhsa
rsv
f
protein
also
determin
elisa
describ
f
protein
purchas
sino
biolog
inc
beij
china
control
assay
hsa
mlhsa
coat
plate
elisa
assay
perform
describ
drugresist
rsv
strain
select
purifi
previous
describ
briefli
cell
seed
plate
corn
acton
usa
cell
infect
rsv
long
strain
wildtyp
strain
moi
presenc
absenc
mlhsa
increas
concentr
start
nm
gradual
increas
nm
viru
passag
continu
show
resist
mlhsa
wildtyp
strain
passag
without
drug
parallel
follow
passag
rsv
long
strain
presenc
mlhsa
first
resist
strain
obtain
nm
passag
mlhsa
pressur
second
resist
viru
strain
nm
obtain
use
resist
strain
sequenc
analysi
viral
rna
extract
supernat
rsvinfect
cell
use
commerci
kit
high
pure
viral
nucleic
acid
kit
roch
diagnost
indianapoli
usa
gene
amplif
primer
use
describ
previou
studi
specif
g
primer
use
perform
revers
transcript
viral
rna
acquir
specif
cdna
g
gene
briefli
extract
rna
primer
combin
mm
dntp
mixtur
firststrand
buffer
dtt
unit
superscript
iirnas
htranscriptas
invitrogen
reaction
volum
mixtur
incub
min
follow
heat
min
rsv
g
protein
gene
amplifi
specif
cdna
gain
nest
pcr
use
primestar
hs
dna
polymeras
takara
japan
primer
set
cycl
paramet
describ
previou
research
pcr
product
second
round
expect
base
pair
bp
visual
electrophoresi
agaros
gel
stain
ethidium
bromid
femal
balbc
mice
six
eight
week
age
purchas
anim
center
fudan
univers
shanghai
china
mice
hous
cage
barrier
filter
certifi
room
fed
water
ad
libitum
protocol
use
anim
studi
approv
anim
center
fudan
univers
permit
number
anim
studi
conduct
strict
accord
recommend
guid
care
use
laboratori
anim
mous
model
rsv
infect
use
examin
vivo
inhibitori
activ
mlhsa
describ
previous
briefli
balbc
mice
chemic
immunosuppress
intraperiton
inject
mg
cyclophosphamid
sigma
per
kg
bodi
weight
day
day
prior
rsv
infect
mice
intranas
administ
differ
dose
mlhsa
mix
pfu
rsv
four
day
rsv
infect
mice
sacrif
lung
homogen
wtvol
prepar
hank
balanc
salt
solut
contain
sucros
mm
hepe
mm
sodium
lglutam
supplement
uml
penicillin
g
streptomycin
amphotericin
b
sigma
lung
homogen
frozen
dri
ice
thaw
releas
cellassoci
viru
sampl
lung
homogen
centrifug
g
min
supernat
collect
viral
titrat
cell
brief
test
sampl
assay
duplic
set
serial
dilut
serumfre
dmem
supplement
mm
lglutamin
u
penicillin
streptomycin
per
ml
dilut
sampl
plate
cell
flatbottom
polystyren
plate
corn
acton
usa
plaqu
assay
perform
describ
evalu
prophylact
effect
mlhsa
mice
intranas
administ
mlhsa
differ
concentr
min
min
later
mice
intranas
inocul
pfu
rsv
respect
day
mice
sacrif
viral
titer
lung
homogen
determin
describ
previou
studi
demonstr
bovin
milk
protein
modifi
anhydrid
becom
highli
potent
inhibitor
hpv
infect
similar
approach
modifi
four
protein
includ
bsa
ova
hsa
hp
ml
su
respect
antivir
activ
infect
rsv
long
strain
test
shown
tabl
except
hp
show
moder
inhibitori
activ
high
concentr
ml
su
exhibit
inhibit
concentr
howev
modifi
protein
exhibit
highli
effect
antivir
activ
long
strain
nanomolar
level
anhydridemodifi
bsa
hsa
efficaci
two
anhydridemodifi
protein
rsv
strain
sensit
rsv
long
strain
anhydridemodifi
protein
although
anhydridemodifi
bsa
exhibit
antirsv
activ
similar
anhydridemodifi
hsa
select
anhydridemodifi
hsa
studi
infant
may
allerg
bsa
bovin
protein
hsa
human
protein
sampl
test
triplic
experi
repeat
twice
data
one
repres
experi
present
mean
sd
vero
cell
b
determin
kit
mlhsa
store
respect
one
twelv
week
follow
assess
antivir
activ
infect
rsv
strain
c
long
strain
respect
detect
indic
time
sampl
test
triplic
experi
repeat
twice
data
one
repres
experi
present
mean
sd
previou
studi
shown
percentag
modifi
arginin
lysin
residu
associ
concentr
anhydrid
use
identifi
anhydrid
optim
concentr
produc
effect
antirsv
agent
use
su
ml
hp
differ
concentr
modifi
hsa
calcul
percentag
modifi
arginin
lysin
residu
well
test
antivir
activ
rsv
strain
long
strain
shown
figur
b
increas
concentr
anhydrid
use
percentag
modifi
arginin
lysin
residu
increas
modifi
protein
gain
potent
antirsv
activ
observ
highli
signific
direct
correl
percentag
modifi
arginin
residu
inhibitori
activ
rsv
long
strain
figur
mlhsa
rsv
rsv
long
strain
r
p
r
p
respect
percentag
modifi
lysin
residu
also
directli
correl
antirsv
activ
anhydridemodifi
protein
figur
f
mlhsa
rsv
rsv
long
strain
r
p
r
p
respect
neither
anhydridemodifi
hsa
unmodifi
hsa
show
signific
cytotox
concentr
high
figur
b
base
result
previou
studi
present
studi
select
averag
ph
mm
anhydrid
optim
paramet
subsequ
experi
sumodifi
hsa
less
efficaci
infect
rsv
long
strain
hpand
mlmodifi
hsa
thu
exclud
suhsa
subsequ
studi
although
hphsa
similar
even
better
antirsv
activ
mlhsa
cost
hp
much
higher
ml
thu
select
mlhsa
studi
studi
stabil
mlhsa
kept
mlhsa
respect
week
detect
antirsv
activ
week
respect
sinc
antirsv
activ
exhibit
signific
chang
storag
period
mlhsa
determin
highli
stabl
figur
determin
step
viru
replic
mlhsa
exert
antivir
effect
mlhsa
ad
differ
time
rsv
infect
supernat
collect
determin
viral
infect
h
postinfect
shown
figur
mlhsa
effect
inhibit
rsv
replic
ad
time
viru
inocul
mlhsa
ad
h
infect
still
display
power
inhibitori
activ
howev
ad
cell
cultur
h
postinfect
percentag
inhibit
mlhsa
reduc
mlhsa
ad
h
postinfect
signific
inhibit
viral
infect
seen
result
suggest
mlhsa
inhibit
rsv
infect
target
earli
step
viru
replic
viral
entri
explor
mechan
action
mlhsa
perform
temperatur
shift
assay
base
report
rsv
could
attach
cell
fusion
target
cell
membran
occur
temperatur
thu
viral
attach
inhibitor
expect
maintain
antivir
activ
ad
mixtur
cell
viru
follow
wash
incub
temperatur
shift
shown
figur
mlhsa
exhibit
similar
antirsv
activ
whether
cell
wash
ad
mixtur
cell
viru
heparin
known
rsv
attach
inhibitor
also
show
similar
antirsv
potenc
whether
cell
wash
figur
data
indic
mlhsa
inhibit
rsv
infect
block
viru
attach
cell
h
follow
wash
remov
unbound
viru
inhibitor
wash
temperatur
shift
cpe
determin
day
plot
cell
viabil
dilut
sampl
test
triplic
experi
repeat
twice
data
one
repres
experi
present
mean
sd
investig
whether
mlhsa
could
block
f
proteinmedi
membran
fusion
perform
cellcel
fusion
assay
use
cell
express
f
protein
induc
tetracyclin
shown
figur
cell
cell
form
syncytia
without
tetracyclin
addit
tetracyclin
syncytia
observ
microscop
concentr
nm
higher
inhibit
rsv
infect
mlhsa
hsa
inhibit
format
syncytia
contrast
nm
significantli
block
syncytium
format
figur
determin
whether
mlhsa
block
viru
attach
cell
interact
rsv
g
protein
perform
enzymelink
immunosorb
assay
elisa
use
antihsa
antibodi
detect
bind
mlhsa
hsa
rsv
g
protein
f
protein
respect
coat
plate
result
show
mlhsa
bound
g
protein
dosedepend
manner
even
concentr
low
nm
mlhsa
still
strongli
bound
g
protein
hsa
exhibit
signific
bind
g
protein
concentr
nm
although
show
weak
bind
concentr
nm
figur
contrast
mlhsa
hsa
show
signific
bind
f
protein
concentr
nm
figur
exclud
possibl
differ
interact
g
protein
hsa
mlhsa
might
result
reduc
reactiv
chemic
modifi
hsa
antihsa
antibodi
perform
anoth
elisa
use
antihsa
antibodi
shown
figur
antihsa
antibodi
bound
hsa
mlhsa
equal
well
suggest
mlmodifi
hsa
maintain
antigen
react
antihsa
antibodi
result
confirm
mlhsa
block
viru
attach
cell
via
interact
rsv
g
protein
sampl
test
triplic
experi
repeat
twice
data
one
repres
experi
present
mean
sd
determin
bind
site
mlhsa
rsv
g
protein
select
viru
strain
resist
mlhsa
compar
sensit
mlhsa
wildtyp
strain
shown
figur
wildtyp
strain
show
high
sensit
mlhsa
valu
nm
resist
strain
exhibit
remark
toler
mlhsa
valu
nm
neither
wildtyp
resist
strain
show
resist
heparin
figur
viral
rna
encod
g
protein
figur
sequenc
analyz
amino
acid
sequenc
g
protein
wildtyp
strain
parent
strain
mlhsa
resist
strain
compar
observ
amino
acid
mutat
g
protein
resist
strain
locat
region
overlap
residu
includ
conserv
domain
residu
data
suggest
mlhsa
may
bind
middl
portion
rsv
g
protein
mous
model
rsv
infect
use
examin
vivo
inhibitori
activ
mlhsa
balbc
mice
n
intranas
administ
mlhsa
singl
dose
mgkg
respect
mix
rsv
long
strain
pfu
four
day
postinfect
mice
sacrif
viral
titer
lung
homogen
measur
shown
figur
viral
titer
untreat
mice
rang
mean
pfu
per
gram
lung
tissu
mean
viral
titer
lung
mice
treat
mgkg
mlhsa
pfu
per
gram
lung
tissu
respect
thu
show
signific
differ
untreat
group
p
mean
viral
titer
lung
mice
treat
mgkg
mlhsa
pfu
per
gram
lung
tissu
respect
significantli
lower
untreat
control
group
p
group
thu
rsv
titer
lung
mice
treat
mgkg
mlhsa
reduc
respect
figur
suggest
mlhsa
concentr
mgkg
effect
inhibit
rsv
replic
vivo
evalu
prophylact
efficaci
mlhsa
mous
model
rsv
infect
intranas
administ
mlhsa
mice
dose
mgkg
min
prior
rsv
inocul
four
day
postinfect
pfu
titer
determin
use
plaqu
assay
viral
control
cohort
show
mean
pfu
per
gram
lung
tissu
group
administ
mlhsa
min
respect
rsv
infect
mean
pfu
per
gram
lung
tissu
respect
figur
viral
titer
mice
treat
mlhsa
min
respect
rsv
infect
significantli
lower
untreat
mice
p
respect
reduct
viral
titer
lung
respect
figur
result
suggest
intranas
administr
mlhsa
effect
prevent
rsv
infect
present
studi
compar
vitro
antirsv
activ
bsa
ova
hsa
modifi
hp
ml
su
respect
anhydridemodifi
protein
exhibit
potent
inhibitori
activ
infect
rsv
long
strain
hpand
mlmodifi
bsa
hsa
found
effect
anhydridemodifi
protein
tabl
select
mlmodifi
hsa
studi
hsa
safer
bsa
human
use
infant
may
allerg
bovin
protein
purchas
price
hp
much
higher
ml
make
product
cost
mlhsa
much
lower
hphsa
addit
ml
common
anhydrid
use
pharmaceut
mccormick
et
al
report
maleic
anhydridedivinyl
ether
copolym
inhibit
mammari
urinari
bladder
carcinogenesi
xie
et
al
demonstr
peptid
modifi
ml
deriv
exhibit
signific
toxic
effect
anim
human
base
toxic
test
mlhsa
show
detect
cytotox
vero
cell
figur
hsa
consist
amino
acid
includ
lysin
residu
arginin
residu
previou
studi
shown
modif
posit
charg
amino
acid
residu
convert
protein
potent
hiv
entri
inhibitor
percentag
modifi
lysin
arginin
residu
depend
concentr
anhydrid
ph
reaction
system
studi
found
optim
ph
valu
system
reaction
optim
concentr
ml
mm
prepar
mlhsa
potent
inhibitori
activ
rsv
infect
figur
b
timeofaddit
assay
mlhsa
exhibit
significantli
decreas
inhibitori
activ
rsv
ad
cultur
cell
viru
one
hour
postvir
infect
figur
suggest
mlhsa
inhibit
rsv
infect
target
earli
stage
viral
replic
use
temperatur
shift
assay
determin
whether
mlhsa
block
viral
attach
bind
target
cell
base
principl
rsv
attach
bind
target
cell
delay
cell
fusion
temperatur
shift
higher
thu
mlhsa
block
viru
attach
fusion
target
cell
still
retain
inhibitori
activ
rsv
replic
unbound
mlhsa
viru
remov
follow
viru
attach
temperatur
rais
higher
shown
figur
mlhsa
similar
whether
unbound
mlhsa
remov
temperatur
shift
confirm
mlhsa
block
attach
rsv
target
cell
possibl
interact
viral
g
protein
inde
mlhsa
bind
g
protein
rsv
dosedepend
manner
shown
elisa
figur
contrast
mlhsa
hsa
show
signific
bind
f
protein
concentr
nm
figur
howev
result
herein
present
could
rule
possibl
mlhsa
might
also
interact
f
protein
higher
concentr
nonspecif
way
addit
purifi
f
protein
test
like
postfus
conform
expect
differ
prefus
conform
rsv
f
protein
therefor
determin
whether
mlhsa
bind
prefus
form
f
protein
warrant
bind
site
mlhsa
viral
g
protein
reveal
induct
rsv
mutant
resist
mlhsa
mutat
residu
locat
region
span
residu
suggest
mlhsa
may
bind
middl
portion
g
protein
interestingli
two
asn
residu
region
substitut
neg
charg
asp
residu
lead
increas
net
neg
charg
bind
site
mlhsa
g
protein
possibl
result
decreas
electrostat
interact
neg
charg
mlhsa
g
protein
rsv
best
knowledg
rsv
vaccin
current
avail
palivizumab
antirsv
mab
use
immunoprophylaxi
prevent
rsv
infect
infant
high
risk
rsv
infect
includ
histori
prematur
chronic
lung
diseas
congenit
heart
diseas
howev
high
cost
prohibit
lowincom
countri
demonstr
studi
mlhsa
highli
effect
inhibit
rsv
infect
vitro
cell
cultur
vivo
mous
model
furthermor
mlhsa
significantli
reduc
titer
rsv
lung
mice
administ
intranas
challeng
rsv
therefor
mlhsa
may
use
prophylact
agent
prevent
rsv
infect
infant
highrisk
immunocompromis
person
rsv
infect
howev
unlik
palivizumab
must
intramuscularli
inject
nurs
doctor
hospit
clinic
doctor
offic
mlhsa
intranas
administ
parent
infant
home
place
intranas
applic
mlhsa
may
approv
overthecount
use
palivizumab
must
maintain
transport
low
temperatur
mlhsa
may
kept
room
temperatur
least
week
base
high
stabil
figur
previou
studi
also
shown
hpmodifi
lg
protein
maintain
antivir
activ
month
kept
room
temperatur
therefor
mlhsa
might
made
nasal
spray
portabl
form
use
infant
high
risk
immunocompromis
person
travel
highrisk
area
hospit
dens
popul
public
area
use
directli
place
acquir
protect
rsv
crossinfect
period
mous
model
rsv
infect
mlhsa
administ
min
prior
rsv
infect
yield
signific
protect
howev
purifi
rsv
high
titer
use
infect
balbc
mice
differ
human
infect
rsv
virion
highrisk
area
suspend
air
low
titer
henc
easili
spread
therefor
actual
use
longer
protect
might
obtain
mlhsa
rsv
infect
topic
outsid
scope
present
work
formul
develop
clinic
trial
make
determin
conclus
maleic
anhydridemodifi
human
serum
albumin
mlhsa
exhibit
potent
inhibitori
activ
rsv
infect
vitro
vivo
bind
viral
g
protein
block
rsv
attach
target
cell
mlhsa
administ
intranas
rsv
infect
led
signific
reduct
viral
titer
lung
mice
result
suggest
mlhsa
promis
therapeut
candid
develop
effect
safe
afford
intranas
regimen
preexposur
prophylaxi
rsv
infect
highrisk
popul
includ
infant
born
prematur
chronic
lung
congenit
heart
diseas
elderli
peopl
immunocompromis
adult
